Proteolytic Cleavage of Apolipoprotein E in the Down Syndrome Brain. 2016

Ryan J Day, and Katie L McCarty, and Kayla E Ockerse, and Elizabeth Head, and Troy T Rohn
1Department of Biological Sciences, Boise State University, Boise, Idaho, 83725, USA.

Down syndrome (DS) is one of the most common genetic causes of intellectual disability and is characterized by a number of behavioral as well as cognitive symptoms. Many of the neuropathological features of early-onset Alzheimer's disease (AD) including senile plaques and neurofibrillary tangles (NFTs) are also present in people with DS as a result of triplication of the amyloid precursor gene on chromosome 21. Evidence suggests that harboring one or both apolipoprotein E4 (APOE4) alleles may increase the risk for AD due to the proteolytic cleavage of apoE4 and a subsequent loss of function. To investigate a role for the apoE proteolysis in vivo, we compared three autopsy groups; 7 DS with AD neuropathology cases over 40 years, 5 young DS cases without AD pathology under 40 years (YDS) and 5 age-matched control cases over 40 years by immunohistochemistry utilizing an antibody that detects the amino-terminal fragment of apoE. Application of this antibody, termed the amino-terminal apoE fragment antibody (nApoECF) revealed labeling of pyramidal neurons in the frontal cortex of YDS cases, whereas in the DS-AD group, labeling with nApoECF was prominent within NFTs. NFT labeling with nApoECF was significantly greater in the hippocampus versus the frontal cortex in the same DS-AD cases, suggesting a regional distribution of truncated apoE. Colocalization immunofluorescence experiments indicated that 52.5% and 53.2% of AT8- and PHF-1-positive NFTs, respectively, also contained nApoECF. Collectively, these data support a role for the proteolytic cleavage of apoE in DS and suggest that apoE fragmentation is closely associated with NFTs.

UI MeSH Term Description Entries

Related Publications

Ryan J Day, and Katie L McCarty, and Kayla E Ockerse, and Elizabeth Head, and Troy T Rohn
July 2009, Experimental & molecular medicine,
Ryan J Day, and Katie L McCarty, and Kayla E Ockerse, and Elizabeth Head, and Troy T Rohn
July 1995, Brain research. Developmental brain research,
Ryan J Day, and Katie L McCarty, and Kayla E Ockerse, and Elizabeth Head, and Troy T Rohn
December 2020, Journal of clinical medicine,
Ryan J Day, and Katie L McCarty, and Kayla E Ockerse, and Elizabeth Head, and Troy T Rohn
May 1997, Neuroreport,
Ryan J Day, and Katie L McCarty, and Kayla E Ockerse, and Elizabeth Head, and Troy T Rohn
April 1999, Journal of lipid research,
Ryan J Day, and Katie L McCarty, and Kayla E Ockerse, and Elizabeth Head, and Troy T Rohn
December 2005, Neuroscience letters,
Ryan J Day, and Katie L McCarty, and Kayla E Ockerse, and Elizabeth Head, and Troy T Rohn
August 2016, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists,
Ryan J Day, and Katie L McCarty, and Kayla E Ockerse, and Elizabeth Head, and Troy T Rohn
September 2015, Neurobiology of disease,
Ryan J Day, and Katie L McCarty, and Kayla E Ockerse, and Elizabeth Head, and Troy T Rohn
September 2004, Journal of neurochemistry,
Ryan J Day, and Katie L McCarty, and Kayla E Ockerse, and Elizabeth Head, and Troy T Rohn
November 2020, Journal of dermatological science,
Copied contents to your clipboard!